Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment by unknown
Song and Xia BMC Ophthalmology  (2015) 15:31 
DOI 10.1186/s12886-015-0017-zRESEARCH ARTICLE Open AccessRanibizumab for macular edema secondary to
retinal vein occlusion: a meta-analysis of dose
effects and comparison with no anti-VEGF
treatment
Wei-tao Song and Xiao-bo Xia*Abstract
Background: To compare the efficacy and tolerability of intravitreal ranibizumab (IVR) 0.5 mg or 0.3 mg with
non-anti-vascular endothelial growth factor (VEGF), and to compare the efficacy of IVR 0.5 mg with IVR 0.3 mg in
the treatment of macular edema secondary to retinal vein occlusion.
Methods: Relevant studies were selected after an extensive search using the PubMed, EMBASE, Web of Science,
and Cochrane Library databases. Outcomes of interest included visual outcomes, anatomic variables, and adverse
events.
Results: Four randomized controlled trials (RCTs) met our inclusion criteria. IVR 0.5 mg produced a significantly
higher improvement in visual acuity at six months, with pooled weighted mean differences (WMDs) of 12.30 early
treatment diabetic retinopathy study (ETDRS) letters (95% CI:10.03, 14.58) (P < 0.001),and led to a higher proportion
of patients gaining ≥15 letters (RR, 2.36; 95%CI: 1.86, 2.99; P < 0.001) at the follow-up endpoint, compared with
non-anti-VEGF. A more obvious reduction in central foveal thickness (CFT) was observed in the IVR 0.5 mg group
than the non-anti-VEGF group, and the mean difference in CFT was statistically significant (WMD, −216.86 μm; 95%
CI: −279.01, −154.71; P < 0.001). A similar efficacy was found between the IVR 0.3 mg group and the non-anti-VEGF
group. No significant differences were found between IVR 0.5 mg and 0.3 mg. The incidence of iris neovascularization
in the non-anti-VEGF group was significantly higher than that of the IVR group.
Conclusions: IVR 0.5 mg or 0.3 mg was more effective than sham injection and laser treatment. IVR 0.3 mg is as effective
as IVR 0.5 mg in the treatment of macular edema secondary to retinal vein occlusion.
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Retinal vein occlusion (RVO) is a common retinal vascu-
lar disorder in which different complications, including
macular edema, may develop with a consequent loss of
central vision [1]. According to the localization of ven-
ous occlusion, central retinal vein occlusion (CRVO) and
branch retinal vein occlusions (BRVO) are the most fre-
quently occurring and clinically relevant types [2]. Both
could result in macular edema, a condition that is char-
acterized by the collection of fluid within the retina,* Correspondence: xbxia21@163.com
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unless otherwise stated.resulting from the breakdown of the blood-retinal bar-
rier and leakage of fluid from the vasculature [3]. It has
been proven that vascular endothelial growth factor
(VEGF) plays a crucial role in this pathological process
[3]. VEGF expression is up-regulated by hypoxia and a
number of other stimuli, and was noted to be elevated in
the ocular fluids of patients with CRVO [4]. Moreover,
intravitreal VEGF levels were observed to correlate with
the severity of clinical findings [5]. Therefore, several
anti-VEGF agents, including ranibizumab, bevacizumab,
and pegaptanib, have been widely used for treating
macular edema [6-9].l. This is an Open Access article distributed under the terms of the Creative
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high-affinity recombinant Fab, which neutralizes all iso-
forms of VEGF [10]. It has been reported to provide
rapid and continuous improvements in best-corrected
visual acuity (BCVA) and rapid reduction of retinal
thickness in the treatment of macular edema [6,7,11].
Two treatment (0.5 mg or 0.3 mg) regimens are often
used when administering ranibizumab. It is unknown
whether the 0.3 mg and 0.5 mg groups may have had
even better outcomes. It is necessary to determine which
dosage is optimal.
Some studies have evaluated the efficacy of intravitreal
ranibizumab (IVR) for treating macular edema in pa-
tients with RVO [6,7,12,13]. Two previous meta-analysis
about treating macular edema secondary to RVO has
been published. However, they both focus on all kinds of
methods, including ranibizumab, bevacizumab, and in-
travitreal dexamethasone, for treating this condition
[14,15]. Moreover, they did not discuss the effect of dif-
ferent doses of ranibizumab. Recently, a high-quality
study on the effectiveness of ranibizumabin treating
macular edema secondary to RVO was published [6].
Therefore, we performed an updated meta-analysis
based only on randomized controlled trials (RCTs) to
compare the efficacy of ranibizumab in conjunction with
non-anti-VEGF (sham or laser), and the efficacy of rani-
bizumab 0.5 mg treatment with ranibizumab 0.3 mg.
Methods
Literature search
A literature search of the PubMed, ISI Web of Science,
EMBASE, and Cochrane library databases was per-
formed to identify relevant studies. The search combined
terms related to drugs (ranibizumab, Lucentis) and
terms related to diseases (macular edema, retinal vein
occlusion), with a filter restricting the results to only
clinical trials. Google Scholar and the websites of profes-
sional associations were also searched for information.
Once relevant articles were identified, their reference
lists were searched for additional articles. The final
search was carried out in April 2014 without restricting
the publication year, language, or methodology.
Inclusion and exclusion criteria
We included full-text publications when the following
inclusion criteria were met: (i) study design—random-
ized clinical trials; (ii) population—patients with macular
edema secondary to RVO; (iii) intervention—IVR 0.5 mg
versus no anti-VEGF treatment, or IVR 0.3 mg versus
no anti-VEGF treatment, or IVR 0.5 mg versus IVR
0.3 mg treatment; (iv) outcome variables—evaluating at
least one of the outcomes of interest mentioned below;
(v) duration—minimum follow-up time was 6 months.
Trials were excluded if (i) they were editorials, letters tothe editor, review articles, case reports, meeting ab-
stracts, or animal experimental studies; or (ii) they were
extensions of the core study with different sample sizes.
Outcome measures
The outcomes included were: (1) the mean changes in
BCVA using ETDRS charts at four meters from the
baseline with different inventions, indicating functional
improvement (continuous); (2) the proportion of pa-
tients who gained or lost ≥ 15 ETDRS letters at the
follow-up endpoint (dichotomous); (3) the mean changes
in central foveal thickness (CFT) from the baseline with
different inventions on ocular coherence tomography
(OCT), indicating anatomical improvement; and (4) the
incidence of adverse events.
Data extraction
Two reviewers (WTS and XBX) independently selected
and assessed the methodological quality of the studies
and performed the data collection in a standardized way.
Disagreements were resolved through discussions and
the achievement of consensus. The following data were
extracted from each study: first author, year of publica-
tion, study design, location of the trial, follow-up period,
sample size, type of diagnosis, treatment regimen, base-
line patient characteristics, inclusion and exclusion cri-
teria, dosage, and outcome. Patients reporting adverse
effects were also recorded.
Quality assessment
The quality assessment was performed according to the
risk-of-bias tool outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (version 5.1.0) [16].
Six key aspects that influence the quality of an RCT
were assessed: sequence generation, allocation conceal-
ment, patient blinding, personnel and outcome asses-
sors, management of incomplete outcome data, and
completeness of outcome reporting, as well as other
potential threats to validity. For each parameter, “yes” in-
dicated a low risk of bias, “no” indicated a high risk of
bias, and “unclear” indicated an unclear or unknown risk
of bias.
Statistical analysis
Data from this meta-analysis are presented in accord-
ance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis [17]. The weighted mean dif-
ferences (WMDs) and risk ratios (RRs) were used to
compare continuous and dichotomous variables, re-
spectively. All outcomes were reported with 95% Confi-
dence intervals (CIs). Considering the different clinical
characteristics among study groups and the variation in
sample sizes, we assumed that heterogeneity was present
even when no statistical significance was identified, and
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model to achieve more conservative estimates [18]. The
statistical heterogeneity between studies was assessed
using the chi-square test, and the quantity of heterogen-
eity was evaluated using the I2 statistic. We performed
the subgroup analyses when comparing IVR 0.5 mg with
non-anti-VEGF treatment. (1) to separately estimate ef-
fects according to the type of RVO; (2) to separately esti-
mate effects for small (<100) and large sample sizes
(>100); (3) to separately estimate effects according to the
control group (sham or laser). However, when compar-
ing IVR 0.3 mg with non-anti-VEGF treatment, this
meta-analysis included only two studies, so we could not
perform the subgroup analysis. The same is true when
comparing IVR 0.5 mg with IVR 0.3 mg treatment. To
investigate the potential for publication bias, we con-
structed standard funnel plots by visually examining
their asymmetry. Publication bias was evaluated using
Begg’s and Egger’s tests [19,20]. P < 0.05 was considered
statistically significant. All statistical analyses were per-
formed using Stata (version 12; Stata Corp, College Sta-
tion, Texas).
Results
Identification of eligible studies
A total of 373 potentially relevant articles were identified
by our literature search, of which 185 were excludedFigure 1 Flowchart of publication search and selection.because they were duplicate studies, and 174 were ex-
cluded based on their titles and abstracts. Of the
remaining 14 that were retrieved for full text review, 6
were excluded due to duplicate data [11,21-25], 2 were
not randomized studies [26,27], 1 was an uncontrolled
study, and the intervention of 1 was not of interest.
Thus, 4 RCTs were included in the final analysis
[6,7,12,13]. Interestingly, 2 articles about CRUISE and
BRAVO [24,25] trials with duplicated data reported
BCVA and CFT at 12 months. However, the sham con-
trol group received pro re nata (PRN) IVR 0.5 mg treat-
ment after 6 months, which might have influenced the
true effect of sham injection. So, we chose the primary
endpoint for this meta-analysis [12,13]. The trial selec-
tion process is shown in Figure 1.
Study characteristics
The main characteristics of the four included RCTs are
shown in Tables 1 and 2. The trials were conducted in
various countries: two were from the United States, one
was from Norway, and one was from Australia. Two tri-
als were carried out with patients with CRVO, and two
were carried out with patients with BRVO. The sample
size ranged from 32 to 397. Among these trials, three
compared IVR 0.5 mg with sham injection, one compared
IVR 0.5 mg with sham injection plus laser treatment, two
Table 1 Characteristics of included RCT studies


















CRUISE (2010) M United States (95site) CRVO 6 m 130 132 130 65.4 ± 13.1 69.7 ± 11.6 65.4 ± 13.1 80/50 71/61 72/58 1) Age > 18 y
2) BCVA between 73 and 24 ETDRS letters
3) RVO duration within 12 months
4) CFT≥ 250 μm
ROCC (2010) M Norway (4 sites) CRVO 6 m 16 16 NA NA NA NA 1) Age > 50 y
2) BCVA between 73 and 6 ETDRS letters
3) CFT≥ 250 μm
BRAVO (2010) M United States (93site) BRVO 6 m 131 134 132 65.2 ± 12.7 66.6 ± 11.2 65.2 ± 12.7 71/60 67/67 74/58 1) Age > 18 y
2) BCVA between 73 to 24 ETDRS
letters
3) RVO duration within 12 months
4) CFT≥ 250 μm
Tan (2014) M Australia (5site) BRVO 12 m 15 21 69.6 ± 11.6 66.7 ± 10.7 8/7 9/12 1) Age > 18 y
2) BCVA between 68 to 20
3) RVO duration between 6 weeks to
9 months.
4) CFT≥ 250 μm
RCT = prospective randomized controlled; RVO = retinal vein occlusion; IVR = intravitreal ranibizumab; M = multicenter; CRVO = central retinal vein occlusion; BCVA = best-corrected visual acuity; ETDRS = Early Treatment














Table 2 Characteristics of treatment exposures included in the meta-analysis
Trial (year) Treatment group Treatment protocol
CRUISE (2010) IVR 0.5 mg (n = 130) IVR 0.5 mg every month for 6 months (6 injections) then PRN (open-label) for 6 months
IVR 0.3 mg (n = 132) IVR 0.3 mg every month for 6 months (6 injections) then PRN (open-label) for 6 months
Sham injection (n = 130) sham injection every month for 6 months (6 injections) then PRN IVR 0.5 mg (open-label)
for 6 months
ROCC (2010) IVR 0.5 mg (n = 16) IVR 0.5 mg every month for 3 months, then as required (at the discretion of the physician)
for persisting macular oedema
Sham injection (n = 16) sham injection (plastic syringe pressed against the eyeball)
BRAVO (2011) IVR 0.5 mg (n = 131) IVR 0.5 mg monthly injections then PRN (open-label) for 6 months
IVR 0.3 mg (n = 134) IVR 0.3 mg monthly injections then PRN (open-label) for 6 months
Sham injection (n = 132) sham injection every month for 6 months (6 injections) then PRN IVR 0.5 mg (open-label)
for 6 months
Tan (2014) IVR 0.5 mg (n = 15) IVR 0.5 mg monthly injections up to month 5 then PRN for 6 months
Sham injection plus laser (n = 21) sham injection monthly up to month 5 then PRN for 6 months, laser at week 13 and 25 if eligible
IVR = intravitreal ranibizumab; PRN = Pro Re Nata.
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pared IVR 0.3 mg with sham injection.
Quality and bias assessment of studies
The included RCTs had some risk of biases (Table 3).
Sequence generation was appropriate in three studies,
and allocation concealment was described in two studies.
In the other two studies, these were unclear. All studies
clearly elaborated upon patient blinding. All studies were
judged to have a low risk of bias from selective report-
ing, because it was clear from the published articles that
all the main pre-specified outcomes had been reported.
Only one study clearly elaborated upon the analysis of
intention-to-treat.
Visual outcomes
In all studies, BCVA was reported to be a mean change
in ETDRS letters, and it was measured by ETDRS letters
from the baseline to follow-up. Pooling the results re-
vealed that treatment with IVR 0.5 mg significantly im-
proved BCVA, compared with non-anti-VEGF (WMD,
12.30 ETDRS letters; 95% CI: 10.03, 14.58; P < 0.001) at
six months. A similar result was found between the IVR
0.3 mg group and non-anti-VEGF group, with a pooled
WMD of 10.26 ETDRS letters (95% CI: −2.59, 2.28).







CRUISE (2010) Yes Unclear Yes Yes
ROCC (2010) Unclear Yes Yes Yes
BRAVO (2011) Yes Unclear Yes Yes
Tan (2014) Yes Yes Yes Yesdifference between the IVR 0.5 mg group and 0.3 mg
group, with a pooled WMD of 1.90 ETDRS letters (95%
CI: −0.35, 4.16; P = 0.098). When comparing the IVR
0.5 mg group and non-anti-VEGF group, we divided the
studies into subgroups according to the type of RVO
(CRVO and BRVO), sample size (>100 and <100), and
different non-anti-VEGF treatment (sham and sham plus
laser). All subgroups showed a statistically significant
difference in favor of the IVR 0.5 mg group. No substan-
tial statistical heterogeneity was observed across studies
(Table 4).
Figure 2 shows that the IVR 0.5 mg demonstrated a
higher proportion of patients who gained ≥15 ETDRS
letters, compared to non-anti-VEGF (RR, 2.36; 95% CI:
1.86, 2.99; P < 0.001) at the follow-up endpoint. IVR
0.3 mg achieved a similar result when compared with
the non-anti-VEGF group (RR, 2.22; 95%CI: 1.58, 3.12;
P < 0.001). However, no significant differences were
found between IVR 0.5 mg and 0.3 mg and the propor-
tion of patients who gained ≥15 ETDRS letters (RR,
1.08; 95% CI: 0.92, 1.26; P < 0.001). No substantial het-
erogeneity was found in these comparisons. Figure 3
shows the results of the proportion of patients who
lost ≥ 15 ETDRS letters by the follow-up endpoint. Non-
anti-VEGF had a higher proportion, compared to IVR









Yes Unclear Yes Yes
Unclear Unclear Yes Yes
Yes Unclear Yes No
Yes Yes Yes Yes
Table 4 Mean change from baseline in BCVA at 6 months
Outcome of interest Studies (n) WMD (95% CI) P Study heterogeneity
χ2 P I2
IVR 0.5 mg vs non-anti-VEGF
Type of RVO
All trials 4 12.30 (10.03,14.58) <0.001 1.66 0.646 0.00%
CRVO 2 14.05 (10.54, 17.56) <0.001 0.02 0.900 0.00%
BRVO 2 11.05 (8.07, 14.02) <0.001 0.01 0.933 0.00%
Sample size
All trials 4 12.30 (10.03,14.58) <0.001 1.66 0.646 0.00%
>100 2 12.43 (9.40, 15.46) <0.001 1.61 0.205 37.9%
<100 2 11.74 (3.98, 19.51) <0.001 0.03 0.868 0.00%
Different non-anti-VEGF treatment
All trials 4 12.30 (10.03,14.58) <0.001 1.66 0.646 0.00%
Sham 3 12.37 (10.02, 14.72) <0.001 1.62 0.446 0.00%
Sham plus laser 1 11.40 (2.64, 20.16) 0.011 -
IVR 0.5 mg vs IVR 0.3 mg 2 1.90 (−0.35, 4.16) 0.098 0.05 0.831 0.00%
IVR 0.3 mg vs non-anti-VEGF 2 10.26 (7.80, 12.72) <0.001 1.11 0.293 9.50%
BCVA = best-corrected visual acuity; WMD = weighted mean differences; OR = odds ratio; CI = confidence interval; IVR = intravitreal ranibizumab; VEGF = vascular
endothelial growth factor; RVO = retinal vein occlusion; CRVO = central retinal vein occlusion; BRVO = branch retinal vein occlusion.
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significant heterogeneity in this analysis.
Central foveal thickness
CFT is considered to be a strong prognostic measure for
ME levels, so it was also assessed in this meta-analysis.
At six months, the pooled result was more effective in
decreasing CFT in the IVR 0.5 mg group, and theFigure 2 Forest plot depicting the meta-analysis for the proportion of p
interval; IVR = intravitreal ranibizumab; VEGF = Vascular endothelial growth facsummary mean difference (WMD: −216.86 μm) was sta-
tistically significant (95% CI: −279.01, −154.71; P <
0.001), compared to the non-anti-VEGF group. A more
obvious reduction in the CFT of the IVR 0.3 mg group
was observed than in the CFT of the non-anti-VEGF
group, and the mean difference in CFT was statistically
significant (WMD, −218.97 μm; 95% CI: −303.31, −134.63;
P < 0.001); however, the corresponding I2 value was 70.5%.atients who gained ≥ 15 ETDRS letters. RR = risk ratio; CI = confidence
tor.
Figure 3 Forest plot depicting the meta-analysis for the proportion of patients who loss ≥ 15 ETDRS letters. RR = risk ratio; CI = confidence
interval; IVR = intravitreal ranibizumab; VEGF = Vascular endothelial growth factor.
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IVR 0.5 mg and 0.3 mg groups (WMD: −12.26 μm;
95% CI: −55.60, 31.08; P = 0.579). Subgroup analyses
comparing the IVR 0.5 mg group to the non-anti-
VEGF group were performed. All the analyses showed
a statistically significant difference in favor of the IVR
0.5 mg group. The pooled estimates for the CFT
change from the baseline to 6 months are summarized in
Table 5.Table 5 Mean change from baseline in CFT at 6 months
Outcome of interest Studies (n) WMD (95% C
IVR 0.5 mg vs non-anti-VEGF
Type of RVO
All trials 4 −216.86 (−279
CRVO 2 −230.84 (−357
BRVO 2 −190.05 (−243
Sample size 4 −216.86 (−279
>100 2 −233.77 (−328
<100 2 −175.95 (−277
Different non-anti-VEGF treatment
All trials 4 −216.86 (−279
Sham 3 −216.42 (−292
Sham plus laser 1 −210.84 (−371
IVR 0.5 mg vs IVR 0.3 mg 2 −12.26 (−55.6
IVR 0.3 mg vs non-anti-VEGF 2 −218.97 (−303
CFT = central foveal thickness; WMD = weighted mean differences; CI = confidence
factor; RVO = retinal vein occlusion; CRVO = central retinal vein occlusion; BRVO = bAdverse events
We compared the incidence of adverse events, combin-
ing the IVR 0.5 mg and IVR 0.3 mg groups with the IVR
group. There was insufficient data about adverse effects,
restricting the ability of meta-analyses to evaluate the ef-
ficacy of adverse effects occurring at different follow-up
points. The meta-analysis could only analyze the adverse
events reported by two trials or more; therefore, we
pooled the eye and non-ocular adverse events of cataractI) P Study heterogeneity
χ2 P I2
.01, −154.71) <0.001 5.57 0.135 46.1%
.63, −104.06) <0.001 3.03 0.082 67.0%
.33, −136.78) <0.001 0.07 0.789 0.00%
.01, −154.71) <0.001 5.57 0.135 46.1%
.83, −138.72) <0.001 4.49 0.034 77.7%
.40, −74.50) <0.001 0.30 0.585 0.00%
.01, −154.71) <0.001 5.57 0.135 46.1%
.99, −139.85) <0.001 5.56 0.062 64.0%
.90, −49.79) <0.001 -
0, 31.08) 0.579 0.06 0.812 0.00%
.31, −134.63) <0.001 3.39 0.066 70.5%
interval; IVR = intravitreal ranibizumab; VEGF = vascular endothelial growth
ranch retinal vein occlusion.
Figure 5 Tests for publication bias for WMD of the BCVA change.
WMD = weighted mean differences.
Song and Xia BMC Ophthalmology  (2015) 15:31 Page 8 of 10formation, iris neovascularization, vitreous hemorrhage,
hypertension, and myocardial infarction (Figure 4). The
pooled results showed that the incidence of cataract for-
mation (RR: 1.07; 95% CI: 0.19, 5.97), vitreous hemor-
rhages (RR: 0.84; 95% CI: 0.44, 1.59), myocardial
infarction (RR: 1.41; 95% CI: 0.22, 9.20), and hyperten-
sion (RR: 1.77; 95% CI: 0.19, 16.55) were comparable in
both the IVR and non-anti-VEGF groups. However, the
incidence of iris neovascularization in the non-anti-
VEGF group was significantly higher than in the IVR
group. No significant heterogeneity was observed in this
analysis.
Publication bias
A funnel plot showing the relatively symmetrical distri-
bution suggested no evidence of publication bias, despite
the small number of trials that were included in this
meta-analysis (Figure 5). Begg’s and Egger’s tests, based
on the mean changes of BCVA, showed that there was
little potential publication bias among the included trials
(Egger’s test, P = 0.958; Begg’s test, P = 0.734).
Discussion
Ranibizumab, a high-affinity recombinant Fab, can in-
hibit all the biological activities of VEGF, and it has been
demonstrated to be effective for treating some ocular
neovascular diseases [12,13,28,29]. In the present meta-
analysis, we have reviewed the literature regarding theFigure 4 Forest plot depicting the meta-analysis for adverse events
CI = confidence interval.efficacy of ranibizumab treatment for macular edema
secondary to retinal vein occlusion, and regarding the
success of different doses of ranibizumab for treating
this visually threatening disease. Using a random-effects
model, the pooled results of four RCTs indicated that
ranibizumab was successful in treating macular edema
secondary to retinal vein occlusion, and that 0.5 mg and
0.3 mg of ranibizumab were comparably effective.
A comparison of IVR 0.5 mg and 0.3 mg versus non-
anti-VEGF showed that both IVR 0.5 mg and 0.3 mg led
to marked improvements, demonstrated by the number
of BCVA ETDRS letters gained and the proportion ofbetween IVR and non-anti-VEGF treatments. RR = risk ratio;
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compared IVR with sham injection and one study com-
pared IVR with laser coagulation treatment; both com-
parisons demonstrated the advantages of IVR therapy.
Ranibizumab was shown to not only prevent further vi-
sion loss, but also to improve visual acuity (≥15 letters
gained) among 47.7–61.1% of patients with macular
edema secondary to retinal vein occlusion [6,12,13]. A
similar trend was also observed in the mean CFT change;
a greater reduction in foveal thickness occurred in patients
treated with IVR 0.5 mg or 0.3 mg.
The pooled results of the present meta-analysis
showed that the IVR 0.5 mg group was associated with a
numerically larger change in BCVA and reduction in
CFT, relative to the IVR 0.3 mg group. However, there
was no significant difference. The results revealed that
both IVR 0.5 mg and 0.3 mg treatment were effective
and had the similar efficacy.
The rising popularity of ranibizumab was accompanied
by concerns about its clinical safety. For example, it may
result in the formation of cataracts, vitreous hemor-
rhages, and arterial thromboembolic events [6,12,13,25].
A comparison of the incidence of adverse events in the
IVR group and non-anti-VEGF group showed that there
was a higher incidence of iris neovascularization in the
non-anti-VEGF group. Unsurprisingly, without the anti-
VEGF treatment, persistently high concentrations of
VEGF in the vitreous and anterior chambers would re-
sult in iris neovascularization. Some have raised con-
cerns about the potential for arterial thromboembolic
events with IVR treatment, but the present analysis sug-
gests that the incidence of myocardial infarction was com-
parable between the two groups. Moreover, Yanagida et al.
[30] undertook a systematic review of the adverse
events associated with ranibizumab and found that it
was systemically safe for treating macular edema. Thus,
the conclusion could be drawn that IVR was a safe
treatment for macular edema secondary to retinal vein
occlusion. However, physicians should pay attention
when administering repeated doses.
For the current meta-analysis, we evaluated the efficacy
and safety of IVR 0.5 mg and 0.3 mg for treating macular
edema secondary to retinal vein occlusion. In an attempt
to produce robust results, we stated rigorous inclusion
criteria before beginning and included only RCTs that
compared the efficacy of ranibizumab and non-anti-VEGF
for treating this disease. Moreover, we performed sub-
group analyses, the results of which suggested that all sub-
groups did not materially alter the pooled results, adding
robustness to our main findings. In this analysis, most
comparisons exhibited no heterogeneity.
Our study had a number of strengths. First, all the
original studies that were included used a randomized
controlled design. Second, the present meta-analyseshad strict inclusion and exclusion criteria. Third, in the
CRUISE [13] and BRAVO [12] studies, the sham injec-
tion group received sham injections every month for
6 months, then PRN IVR 0.5 mg for 6 months. Thus,
we only extracted the outcome of month 6 to avoid
crossover of the treatment groups. Fourth, we strictly
followed the Cochrane Handbook for Systematic Re-
views of Interventions and the PRISMA statement
when performing the literature search, data extraction,
quality assessment, and statistical analysis. This makes
our conclusions more scientific and reliable. Thus, this
meta-analysis contributes robust information to this
area of study.
Although the present analysis represents a complete
summary of the currently available evidence for the effi-
cacy of IVR 0.5 mg or 0.3 mg for treating macular
edema secondary to retinal vein occlusion, it also serves
to highlight any limitations. The main weakness of the
analysis is the short follow-up times of the included
studies. Longer follow-ups after the last injection or lon-
ger periods of repeated injections would have provided
more certainty regarding treatment recommendations.
Another potential limitation is that the included trials
contained two types of RVO. This factor may result in
heterogeneity, and could impact our results. However,
subgroup analyses showed that the CRVO and BRVO
subgroups had similar results and did not alter the
pooled results. Additionally, the small number of trials
eligible for our meta-analysis made it difficult to acquire
enough data for meaningful results. Fourth, the sample
sizes of some of the included studies were small. For ex-
ample, Tan’s [6] trial only included 36 participants,
which substantially increases the risk of a type II error.
The fifth limitation is that the analyses of adverse events
outcome measures were based on data pooled from tri-
als with different follow-up periods. Finally, as we can-
not attempt to gain access to unpublished results,
publication bias cannot be fully excluded.Conclusions
In conclusion, the current limited evidence suggests that
ranibizumab is more effective than sham injection and
laser treatment. IVR 0.3 mg is as effective as IVR 0.5 mg
for treating macular edema secondary to retinal vein oc-
clusion. However, long-term data on the effectiveness
and safety of this treatment method are needed.
Competing interests
The authors declare that they have no competing interests. There are no
sources of financial support to declare in this paper.
Authors’ contributions
All authors conceived of and designed the experimental protocol. SW
collected the data. All authors were involved in the analysis. SW wrote the
first draft of the manuscript. XX reviewed and revised the manuscript and
Song and Xia BMC Ophthalmology  (2015) 15:31 Page 10 of 10produced the final version. Both authors read and approved the final
manuscript.Acknowledgements
This research was supported by grants from National Scientific Foundation of
China (No. 81400400).Supports
This research was supported by grants from National Scientific Foundation of
China (No. 81400400).
Received: 16 October 2014 Accepted: 17 March 2015
References
1. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal
vein occlusion: review of the literature. Eye (Lond). 2011;25:981–8.
2. Wong TY, Scott IU. Clinical practice Retinal-vein occlusion. N Engl J Med.
2010;363:2135–44.
3. Vinores SA, Derevjanik NL, Ozaki H, Okamoto N, Campochiaro PA. Cellular
mechanisms of blood-retinal barrier dysfunction in macular edema. Doc
Ophthalmol. 1999;97:217–28.
4. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular
endothelial growth factor in ocular fluid of patients with diabetic
retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–7.
5. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA, et al.
Correlation of increased vascular endothelial growth factor with
neovascularization and permeability in ischemic central vein occlusion. Arch
Ophthalmol. 2002;120:1644–50.
6. Tan MH, McAllister IL, Gillies ME, Verma N, Banerjee G, Smithies LA, et al.
Randomized controlled trial of intravitreal ranibizumab versus standard grid
laser for macular edema following branch retinal vein occlusion. Am J
Ophthalmol. 2014;157:237–47.
7. Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, et al.
Efficacy of ranibizumab in patients with macular edema secondary to
central retinal vein occlusion: results from the sham-controlled ROCC study.
Am J Ophthalmol. 2010;150:310–4.
8. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti
SD, et al. A 2-year prospective randomized controlled trial of intravitreal
bevacizumab or laser therapy (BOLT) in the management of diabetic
macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130:972–9.
9. Wroblewski JJ, Wells JR, Adamis AP, Buggage RR, Cunningham EJ,
Goldbaum M, et al. Pegaptanib sodium for macular edema secondary to
central retinal vein occlusion. Arch Ophthalmol. 2009;127:374–80.
10. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of
ranibizumab, an anti-vascular endothelial growth factor antigen binding
fragment, as therapy for neovascular age-related macular degeneration.
Retina. 2006;26:859–70.
11. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, et al. Ranibizumab
for macular edema due to retinal vein occlusions: long-term follow-up in
the HORIZON trial. Ophthalmology. 2012;119:802–9.
12. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al.
Ranibizumab for macular edema following branch retinal vein occlusion:
six-month primary end point results of a phase III study. Ophthalmology.
2010;117:1102–12.
13. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al.
Ranibizumab for macular edema following central retinal vein occlusion:
six-month primary end point results of a phase III study. Ophthalmology.
2010;117:1124–33.
14. Pielen A, Feltgen N, Isserstedt C, Callizo J, Junker B, Schmucker C. Efficacy
and safety of intravitreal therapy in macular edema due to branch and
central retinal vein occlusion: a systematic review. PLoS One. 2013;8:e78538.
15. Glanville J, Patterson J, McCool R, Ferreira A, Gairy K, Pearce I. Efficacy and
safety of widely used treatments for macular oedema secondary to retinal
vein occlusion: a systematic review. BMC Ophthalmol. 2014;14:7.
16. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of
Interventions. Version 5.1.0 (updated March 2011): Section 7.7.3.5 The
Cochrane Collaboration 2008. Available at: http://www.cochrane-handbook.
org/. Accessed May 05, 2008.17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. J Clin
Epidemiol. 2009;62:1006–12.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.
1986;7:177–88.
19. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected
by a simple, graphical test. BMJ. 1997;315:629–34.
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test
for publication bias. Biometrics. 1994;50:1088–101.
21. Thach AB, Yau L, Hoang C, Tuomi L. Time to Clinically Significant Visual
Acuity Gains after Ranibizumab Treatment for Retinal Vein Occlusion: BRAVO
and CRUISE Trials. Ophthalmology. 2014;121:1059–66.
22. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, et al.
Long-term outcomes in patients with retinal vein occlusion treated with
ranibizumab: the RETAIN study. Ophthalmology. 2014;121:209–19.
23. Varma R, Bressler NM, Suner I, Lee P, Dolan CM, Ward J, et al. Improved
vision-related function after ranibizumab for macular edema after retinal
vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology.
2012;119:2108–18.
24. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, et al.
Sustained benefits from ranibizumab for macular edema following central
retinal vein occlusion: twelve-month outcomes of a phase III study.
Ophthalmology. 2011;118:2041–9.
25. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, et al.
Sustained benefits from ranibizumab for macular edema following branch
retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology.
2011;118:1594–602.
26. Pacella E, Pacella F, La Torre G, Impallara D, Malarska K, Brillante C, et al.
Testing the effectiveness of intravitreal ranibizumab during 12 months of
follow-up in venous occlusion treatment. Clin Ter. 2012;163:e413–22.
27. Figueroa MS, Contreras I. Potential anti-vascular endothelial growth factor
therapies for central retinal vein occlusion. Drugs. 2012;72:2063–71.
28. Menke MN, Zinkernagel MS, Ebneter A, Wolf S. Functional and anatomical
outcome of eyes with neovascular age-related macular degeneration
treated with intravitreal ranibizumab following an exit strategy regimen. Br J
Ophthalmol. 2014;98:1197–200.
29. Sawada T, Kakinoki M, Wang X, Kawamura H, Saishin Y, Ohji M. Bimonthly
injections of ranibizumab for age-related macular degeneration. Graefes
Arch Clin Exp Ophthalmol. 2014;252:1545–51.
30. Yanagida Y, Ueta T. Systemic safety of ranibizumab for diabetic macular
edema: meta-analysis of randomized trials. Retina. 2014;34:629–35.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
